NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Trading Volume Surges on Positive CLR 131 Report
Shares of Cellectar Biosciences (NASDAQ: CLRB) are up 9%, continuing a pre-market surge and moving on volume of 4.8 million, compared to the 30-day average of 86,851, after the company said that CLR 131 has achieved a median overall survival of 22.5 months to date in patients with multiple myeloma. The company’s ongoing phase 1 clinical trial surpasses historic published outcomes of currently marketed second and third line treatment modalities for multiple myeloma and could continue to increase over time. “We continue to make meaningful progress on our CLR 131 program and are encouraged by the observed clinical outcomes to…







